It recorded a net loss of $74.8 million. Diluted earnings per share were -$0.80.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|
| Research and development |
—
|
—
|
—
|
5
-30.1%
|
7
+31.2%
|
7
+153.6%
|
7
+245.1%
|
8
+112.5%
|
| Selling, general and administrative |
—
|
—
|
—
|
9
+93.0%
|
6
+76.5%
|
6
+82.1%
|
5
+115.4%
|
5
+62.4%
|
| Net income |
-75
-487.9%
|
-10
+20.7%
|
-15
-18.6%
|
-14
-15.4%
|
-13
-50.3%
|
-13
-97.5%
|
-12
-125.7%
|
-13
-76.0%
|
| Basic EPS |
-0.80
-116.2%
|
-0.19
+48.6%
|
-0.27
+23.7%
|
-0.28
+22.2%
|
-0.37
-48.0%
|
-0.37
-42.3%
|
-0.36
-38.4%
|
-0.36
-5.9%
|
| Diluted EPS |
-0.80
-116.2%
|
-0.19
+48.6%
|
-0.27
+23.7%
|
-0.28
+22.2%
|
-0.37
-48.0%
|
-0.37
-42.3%
|
-0.36
-38.4%
|
-0.36
-5.9%
|
| Weighted average shares, basic |
94
+169.6%
|
53
+53.9%
|
54
+55.5%
|
51
+48.5%
|
35
+1.1%
|
35
+38.5%
|
35
+63.0%
|
34
+62.6%
|
| Weighted average shares, diluted |
94
+169.6%
|
53
+53.9%
|
54
+55.5%
|
51
+48.5%
|
35
+1.1%
|
35
+38.5%
|
35
+63.0%
|
34
+62.6%
|
| Other measures | ||||||||
| Depreciation and amortization |
0
+5.5%
|
0
-8.1%
|
0
-1.7%
|
0
-5.3%
|
0
-3.5%
|
0
+8.8%
|
0
+1.8%
|
0
-1.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ACHV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 949858
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (until Jul 31, 2017); SONUS PHARMACEUTICALS INC (until Aug 7, 2008)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.